Danofloxacin
Chemical compound
- QJ01MA92 (WHO)
- 1-Cyclopropyl-6-fluoro-7-[(1S,4S)-3-methyl-3,6-diazabicyclo[2.2.1]heptan-6-yl]-4-oxoquinoline-3-carboxylic acid
- 112398-08-0 Y
- 71335
- 64439 N
- 24CU1YS91D
- ChEMBL157548 N
- DTXSID0046432
- Interactive image
- O=C(O)\C4=C\N(c3cc(N1C[C@H]2N(C)C[C@@H]1C2)c(F)cc3C4=O)C5CC5
InChI
- InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1 N
- Key:QMLVECGLEOSESV-RYUDHWBXSA-N N
Danofloxacin is a fluoroquinolone antibiotic used in veterinary medicine.[1]
References
- ^ Lees P, Shojaee Aliabadi F (April 2002). "Rational dosing of antimicrobial drugs: animals versus humans". International Journal of Antimicrobial Agents. 19 (4): 269–84. doi:10.1016/s0924-8579(02)00025-0. PMID 11978498.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation | |||||||||
---|---|---|---|---|---|---|---|---|---|
Fluoroquinolones |
| ||||||||
Newer non-fluorinated | |||||||||
Related (DG) |
inhibitors
Nitroimidazole derivatives |
---|
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e